[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-KROS":3,"homepage-market-summary":31,"stock-news-KROS":173},{"ticker":4,"date":5,"profile":6,"dividend":9,"quote":15},"KROS","2026-10-05",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":13,"founded":9,"is_fund":14,"issuer":9,"category":9},"Keros Therapeutics, Inc. Common Stock","Nasdaq",null,"PHARMACEUTICAL PREPARATIONS","Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.","92","Lexington, MA",false,{"close":16,"open":17,"high":18,"low":19,"prev_close":20,"change":21,"percent_change":22,"volume":23,"transactions":24,"vwap":25,"high_52w":26,"low_52w":27,"avg_volume_52w":28,"range_52w_percent":29,"record_count":30},11.52,11.38,11.56,11.07,11.36,0.16,1.41,132405.585201,4240,11.4004,22.55,9.69,490443.1019014024,14.2,1631,{"status":32,"indices":33,"watchlist":76,"sectors":98,"benchmarks":153},"success",[34,42,49,56,63,69],{"symbol":35,"name":36,"price":37,"change":38,"pct_change":39,"is_up":40,"sparkline":41,"date":5},"SPX","S&P 500",7773.95,51.23,0.66,true,"0.0,8.3 2.3,10.7 4.6,13.5 6.9,9.4 9.3,11.7 11.6,13.9 13.9,16.0 16.2,10.6 18.5,9.8 20.8,2.6 23.2,2.6 25.5,6.3 27.8,6.4 30.1,3.9 32.4,7.7 34.7,8.5 37.1,9.7 39.4,8.8 41.7,5.2 44.0,2.0",{"symbol":43,"name":44,"price":45,"change":46,"pct_change":47,"is_up":40,"sparkline":48,"date":5},"NDX","NASDAQ 100",31076.44,268.51,0.87,"0.0,12.3 2.3,12.8 4.6,14.9 6.9,13.2 9.3,14.8 11.6,16.0 13.9,16.0 16.2,12.7 18.5,11.4 20.8,5.9 23.2,4.3 25.5,6.0 27.8,5.9 30.1,5.1 32.4,7.2 34.7,6.8 37.1,6.4 39.4,5.8 41.7,3.8 44.0,2.0",{"symbol":50,"name":51,"price":52,"change":53,"pct_change":54,"is_up":40,"sparkline":55,"date":5},"DJI","DOW JONES",51268,91,0.18,"0.0,2.0 2.3,5.0 4.6,7.4 6.9,3.6 9.3,4.7 11.6,7.2 13.9,11.9 16.2,9.5 18.5,10.2 20.8,7.5 23.2,8.9 25.5,11.5 27.8,12.7 30.1,9.1 32.4,11.7 34.7,12.7 37.1,16.0 39.4,15.8 41.7,14.0 44.0,13.3",{"symbol":57,"name":58,"price":59,"change":60,"pct_change":61,"is_up":40,"sparkline":62,"date":5},"COMP","NASDAQ Composite",27477.31,286.45,1.05,"0.0,11.9 2.3,13.4 4.6,15.0 6.9,12.7 9.3,14.1 11.6,16.0 13.9,16.0 16.2,11.9 18.5,10.9 20.8,5.3 23.2,4.2 25.5,7.1 27.8,7.0 30.1,5.8 32.4,8.1 34.7,8.3 37.1,7.8 39.4,7.7 41.7,4.7 44.0,2.0",{"symbol":64,"name":65,"price":66,"change":67,"pct_change":39,"is_up":40,"sparkline":68,"date":5},"RUT","RUSSELL 2000",2833.8,18.6,"0.0,2.0 2.3,5.4 4.6,7.8 6.9,6.8 9.3,8.3 11.6,10.0 13.9,11.0 16.2,9.7 18.5,10.8 20.8,9.6 23.2,8.2 25.5,12.6 27.8,12.9 30.1,12.6 32.4,14.2 34.7,15.1 37.1,16.0 39.4,15.1 41.7,13.0 44.0,11.4",{"symbol":70,"name":71,"price":72,"change":73,"pct_change":74,"is_up":40,"sparkline":75,"date":5},"VIX","CBOE VIX",15.52,0.21,1.37,"0.0,10.2 2.3,7.3 4.6,2.0 6.9,9.7 9.3,4.9 11.6,4.5 13.9,2.5 16.2,11.3 18.5,13.7 20.8,13.5 23.2,16.0 25.5,12.3 27.8,10.4 30.1,13.5 32.4,8.8 34.7,8.9 37.1,7.8 39.4,7.6 41.7,11.8 44.0,10.9",[77,84,91],{"symbol":78,"name":79,"price":80,"change":81,"pct_change":82,"is_up":40,"sparkline":83,"date":5},"NVDA","NVIDIA Corp",238.9,4.95,2.12,"0.0,16.0 7.3,12.2 14.7,13.8 22.0,12.6 29.3,10.1 36.7,7.0 44.0,2.0",{"symbol":85,"name":86,"price":87,"change":88,"pct_change":89,"is_up":14,"sparkline":90,"date":5},"AAPL","Apple Inc",332.89,-0.8,-0.24,"0.0,2.0 7.3,5.2 14.7,16.0 22.0,11.7 29.3,14.9 36.7,10.9 44.0,11.8",{"symbol":92,"name":93,"price":94,"change":95,"pct_change":96,"is_up":40,"sparkline":97,"date":5},"TSLA","Tesla Inc",378.69,8.1,2.18,"0.0,5.6 7.3,13.5 14.7,16.0 22.0,14.9 29.3,15.3 36.7,6.4 44.0,2.0",[99,104,109,114,119,124,129,134,139,144,148],{"name":100,"etf":101,"change":102,"price":103,"is_up":40},"Technology","XLK",0.56,200.93,{"name":105,"etf":106,"change":107,"price":108,"is_up":40},"Financials","XLF",0.73,53.88,{"name":110,"etf":111,"change":112,"price":113,"is_up":40},"Healthcare","XLV",0.72,167.37,{"name":115,"etf":116,"change":117,"price":118,"is_up":40},"Consumer Cycl","XLY",0.35,110.42,{"name":120,"etf":121,"change":122,"price":123,"is_up":40},"Consumer Staples","XLP",0.63,81.04,{"name":125,"etf":126,"change":127,"price":128,"is_up":40},"Energy","XLE",0.99,63.44,{"name":130,"etf":131,"change":132,"price":133,"is_up":40},"Industrials","XLI",0.09,170.1,{"name":135,"etf":136,"change":137,"price":138,"is_up":40},"Materials","XLB",1.31,49.5,{"name":140,"etf":141,"change":142,"price":143,"is_up":14},"Real Estate","XLRE",-0.34,40.67,{"name":145,"etf":146,"change":117,"price":147,"is_up":40},"Utilities","XLU",39.97,{"name":149,"etf":150,"change":151,"price":152,"is_up":40},"Comm Services","XLC",1.17,111.61,[154,159,164,169],{"ticker":155,"name":156,"price":157,"change":158,"is_up":40},"SPY","SPDR S&P 500 ETF",774.83,0.67,{"ticker":160,"name":161,"price":162,"change":163,"is_up":40},"QQQ","Invesco QQQ Trust",756.2,0.88,{"ticker":165,"name":166,"price":167,"change":168,"is_up":40},"DIA","SPDR Dow Jones ETF",512.11,0.2,{"ticker":170,"name":171,"price":172,"change":39,"is_up":40},"IWM","iShares Russell 2000",283.39,{"ticker":4,"count":174,"articles":175},8,[176,182,188,194,200,205,210,216],{"title":177,"link":178,"pubDate":179,"description":180,"source":181},"Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Average Target Price of $20.50 According to Brokerages - MarketBeat","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi8wFBVV95cUxPcklCdkVSbHpfNzZwR2lWMjZVcTJQa2VzN0xEWE9zQmNjRHFiaUhWUjdTX0lzdEFaaVBmMExnRGQzSkVlQnpSR1ZpelRUNHllck1KZl9IMWJncGVqS1VzVjViS091eHdpX1ZjVENKVklzd2s5S2Q1Q3RXVC1sbGhfejJGT29laWdtVGtnZEd3RExkeVNlZ1c2RnE2d3ZxWFM5RG41VnFEcFVKUVZGeklhVW44cldhRGVSbERQb0R6enNGcWFhSU95Y2lEZWJmX3o2RTV4WXFzcmFrMXFDT3VOTUZUc2hnXzE5Q3h3a3pTdWlVWFk?oc=5","Tue, 29 Sep 2026 06:50:51 GMT","Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Average Target Price of $20.50 According to Brokerages MarketBeat","MarketBeat",{"title":183,"link":184,"pubDate":185,"description":186,"source":187},"KROS Begins Dosing in Phase II Study With Rinvatercept in DMD - Yahoo Finance","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMikgFBVV95cUxQdXJnQVRpUzR0azgxR1Fhd3ZjZzBDdktKTHFKcVZDaGktSXBJMDBDX01PaThMWWhZSGJXS09VTzJqR0U1MlkxM0E2aDU3SENWM0w3WG5aY0pyNS12SXdOZkNjQ0pPdUdXR2JRRWVpRk95MmVNelZnLVNLeEZiTm42QklQdFVhZXZSLXhHRU9aMTk0QQ?oc=5","Tue, 29 Sep 2026 13:17:00 GMT","KROS Begins Dosing in Phase II Study With Rinvatercept in DMD Yahoo Finance","Yahoo Finance",{"title":189,"link":190,"pubDate":191,"description":192,"source":193},"Keros Therapeutics Expects $20 Million Milestone Payment After First Patient Dosed in Takeda’s ELRiSE MF Phase 3 Trial - Quiver Quantitative","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi8AFBVV95cUxPYUN6dnc1TGRZR1hURC1MWmNkN2REbTQ2M2ZQYm1uV3ZwQTF5dVM0Zy1pMXNhajlwSWxISmM1SDBfeF9uVjV0NS10ejI1cDItQV9fOE92bmFTNjRfVkF2RVNKejM0RDRLbHRmZ0p4aWsxb0MyR3BRa0xKWmZjVVQzVFc2WWJHbFdyWklscUM3cGNHYTFEdHV5dWpQcXFKZm1OZXpFODJmYllrT1hEeW1ST0ZDX1RUUzAyYmNBNmxrOXBlcmw3ZHNZSkZnVkdFY09uV2ViaE5aOXhyRmFfMHNER1hHZkJaVmE0M3o3WE0xbjA?oc=5","Tue, 29 Sep 2026 12:13:00 GMT","Keros Therapeutics Expects $20 Million Milestone Payment After First Patient Dosed in Takeda’s ELRiSE MF Phase 3 Trial Quiver Quantitative","Quiver Quantitative",{"title":195,"link":196,"pubDate":197,"description":198,"source":199},"Price-Driven Insight from (KROS) for Rule-Based Strategy - news.stocktradersdaily.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMizwFBVV95cUxNUmRyY3RMX1BRZy1jYTB3QWdROEJmYk1ZUzdHbG1seUl3OWpTeEVvZlhMZmdwd0xFOG9GQVI3NDJpVGU0cTNnMXZRSkZfMzFGYjNURERmX0JfVUFzVDZsWUFid2poanpfZWpwbW9RNDF3YVlva3dYY3RqUG4tWHhpNEd2T29DcTRrbW9Xa2QxQnlqQUVSSGgySHVSNk9jQ01FTVVfOWZ5WGd5NXpnT0tCSDl3V1RlWjh2aXVYVGVYT2VCbkJTZC14UUE3TXIzRnc?oc=5","Thu, 24 Sep 2026 16:04:01 GMT","Price-Driven Insight from (KROS) for Rule-Based Strategy news.stocktradersdaily.com","news.stocktradersdaily.com",{"title":201,"link":202,"pubDate":203,"description":204,"source":187},"Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD - Yahoo Finance","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMipgFBVV95cUxPRjd4S0djelJKcGhxaFVpU3hZZXlhU3FuMDRRVFhVVzRpZ3JvV3NEME0xM2FLYl9RQWxveS10NC1nd3pFZFBucXJ4TU5qWVpUMkNDazYwTE9uckpPYUptWVl5aWFXZUp3eHBFRWJkZmRWeW12Qnc0Tkxfb0tkNXZPWlRuQzhIUjh5T3hZU0pnUl9UR1NrNjdwck9aNzM5eC1SX3owYXR3?oc=5","Mon, 28 Sep 2026 07:00:00 GMT","Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD Yahoo Finance",{"title":206,"link":207,"pubDate":208,"description":209,"source":199},"How (KROS) Movements Inform Risk Allocation Models - news.stocktradersdaily.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMixwFBVV95cUxNZjBxVHA3bklGTGNaOUdodm9FUkhmanhaZGlyNVJKQkZZdXBXUWNtYng3T1N0MzJocC1WZG5ObjBqaXpwRUpQcm9rS0dfQnpXT3BtWUx6OW9iVmM2RzI1UU5pTl9lalVQOHhrMl9PMHZWT1VtdmgyX3dSRHItUlJ6MTM0RGF2dmloZW9BOTA1RHhLSGxRd2FtRHpOSDgzSlh3dXBWTWJibWVKdVFZWDVqSVkxel9WXzhlSkpWRGFPaFNkLVd6dUpj?oc=5","Sun, 04 Oct 2026 23:00:02 GMT","How (KROS) Movements Inform Risk Allocation Models news.stocktradersdaily.com",{"title":211,"link":212,"pubDate":213,"description":214,"source":215},"Keros Therapeutics earns milestone for Phase 3 myelofibrosis trial - TipRanks","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiugFBVV95cUxPUzJpS1RISGU2dUxnRFl6MDdQMm0wSzJwbWMzZUdJY2I5SURybi1tOGVlSmR0S3pHbkdjUmtvamh1UnNTbE95NlIwUVNlaTIwcnNCYWhDbTVicEwxTm5ZZGl3aUdOc3J0Ylc3MGU5ZFdrNmxLbjVyOXdtdDI3OE9sLUs5QzJONlp0cE1yVkpQWU5pTzA0c25GNWIzeXh3NDVkUmprWlVab3ZUSmVkQmlRYW5rdHB3RHJCQUE?oc=5","Tue, 29 Sep 2026 12:38:55 GMT","Keros Therapeutics earns milestone for Phase 3 myelofibrosis trial TipRanks","TipRanks",{"title":217,"link":218,"pubDate":219,"description":220,"source":215},"Keros Begins Phase 2 Rinvatercept Trial in DMD - TipRanks","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMinwFBVV95cUxPYjEzdkkxV1BJMmxLbDZYQzJZNjRMRVF5dEJMVzdBdXpDMEtZeTlBbUFsdXJvdHNWbDZ1Mjh3dlc0dHRiZ285WlRjU1k2dlJ4MWozbG5SeG9qbHZzNm9TRHJHUlVDbmVPVWFSWmxOV2IzOGI5eHNaOV91MXRLb29oOFJ2R2FRWTVicVFNcUoxX2pJX2pxQUtfSlhzUG1nS1k?oc=5","Mon, 28 Sep 2026 13:18:12 GMT","Keros Begins Phase 2 Rinvatercept Trial in DMD TipRanks"]